Indication
Neuroendocrine Tumor (Gastrointestinal)
1 clinical trial
2 products
Clinical trial
Phase 1 Trial Using 131I MIBG and 90Y DOTATOC in a Dosimetrically Determined Optimal Combination for Therapy of Selected Patients With Midgut Neuroendocrine Tumors.Status: Active (not recruiting), Estimated PCD: 2025-12-01
Product
90Y-DOTA-3-Tyr-OctreotideProduct
131I-MIBG